Skip to content
DataLookout
Menu

NCT07895056

A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) ABBV-706 in Combination With Tarlatamab and Atezolizumab in Adult Participants With Extensive Stage-Small Cell Lung Cancer

StatusNot Yet Recruiting
PhasePhase 2
SponsorAbbVie
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

Objective Response (OR) measured by overall response rate (ORR) Based on Blinded Independent Central Review (BICR) Assessment Per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1
Timeframe: Up to Approximately 4 Years
Number of Participants with Adverse Events (AEs)
Timeframe: Up to Approximately 4 Years

Secondary (4)

Duration of Response (DoR) Based on BICR Per RECIST v1.1
Disease Control (DC) Based on BICR Per RECIST v1.1
Overall Survival (OS)
Progression-Free Survival (PFS) Based on BICR Per RECIST v1.1

Arms and interventions

ABBV-706 Dose A + Tarlatamab + AtezolizumabExperimental

Participants will receive ABBV-706 dose A in combination with atezolizumab and tarlatamab during the safety lead-in and dose expansion periods.

ABBV-706 Dose B + Tarlatamab + AtezolizumabExperimental

Participants will receive ABBV-706 dose B in combination with atezolizumab and tarlatamab during the safety lead-in and dose expansion periods.

Drugs: ABBV-706, Tarlatamab, Atezolizumab